Dr. Mahantshetty Discusses Results of Chemoradiation in Cervical Cancer

Umesh Mahantshetty, MD, MBBS
Published: Tuesday, Nov 07, 2017



Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

In a trial of patients with stage IIIB squamous cell carcinoma of the uterine cervix, cisplatin chemoradiation and radiation were compared. The aim was to see whether chemoradiation was beneficial in this population.

An absolute benefit of 8% and 8.5% for disease-free survival and overall survival was observed in the chemoradiation arm.
 


Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

In a trial of patients with stage IIIB squamous cell carcinoma of the uterine cervix, cisplatin chemoradiation and radiation were compared. The aim was to see whether chemoradiation was beneficial in this population.

An absolute benefit of 8% and 8.5% for disease-free survival and overall survival was observed in the chemoradiation arm.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x